Signet Healthcare Partners
Signet Healthcare Partners is a New York–based growth equity firm that provides growth capital to commercial-stage healthcare companies, primarily in specialty pharmaceuticals, pharmaceutical services (including CDMOs), medical devices and diagnostics. The firm partners actively with management teams, typically taking board roles and providing strategic, commercial and operational support to scale revenue and build value.
Industries
Nr. of Employees
small (1-50)
Signet Healthcare Partners
Carnegie Hall Tower, 152 West 57th Street, 59th Fl, New York, NY 10019
Portfolio
Signet led a $25M Series B in March 2023 and supported an add-on acquisition; Paragonix was later acquired by Getinge (announced September 2024).
#Medical devices — organ preservation and transplantation
Signet led a consortium investment of $93 million to support Pii's manufacturing and formulation expansion; Signet's James Gale joined the Pii Board.
#Pharmaceutical services — CDMO (formulation development and cGMP manufacturing)
Signet made a growth investment to support facility expansion, service-line broadening and U.S. commercial reach; James Gale joined the Board.
#Biologics CDMO — recombinant proteins, vaccines, cell therapies
Signet co-invested alongside existing shareholders to accelerate facility capabilities and growth; Signet placed a board representative and supported CEO appointment.
#Pharmaceutical services — CDMO (BFS, nasal spray, aseptic liquid manufacturing)
Financing used to commercialize the G-EYE® product and pursue FDA clearance and U.S. commercial operations.
#Medical devices — endoscopy (G-EYE® colonoscopy device)
Investment used to support R&D, pipeline expansion and repay existing indebtedness; Signet board representation planned.
#Pharmaceuticals — generic pharmaceuticals (oral solids manufacturing)
Signet led a $25M Series B in March 2023 and supported an add-on acquisition; Paragonix was later acquired by Getinge (announced September 2024).
#Medical devices — organ preservation and transplantation
Signet led a consortium investment of $93 million to support Pii's manufacturing and formulation expansion; Signet's James Gale joined the Pii Board.
#Pharmaceutical services — CDMO (formulation development and cGMP manufacturing)
Signet made a growth investment to support facility expansion, service-line broadening and U.S. commercial reach; James Gale joined the Board.
#Biologics CDMO — recombinant proteins, vaccines, cell therapies
Signet co-invested alongside existing shareholders to accelerate facility capabilities and growth; Signet placed a board representative and supported CEO appointment.
#Pharmaceutical services — CDMO (BFS, nasal spray, aseptic liquid manufacturing)
Financing used to commercialize the G-EYE® product and pursue FDA clearance and U.S. commercial operations.
#Medical devices — endoscopy (G-EYE® colonoscopy device)
Investment used to support R&D, pipeline expansion and repay existing indebtedness; Signet board representation planned.
#Pharmaceuticals — generic pharmaceuticals (oral solids manufacturing)